Crk at the quarter century mark: Perspectives in signaling and cancer

Journal of Cellular Biochemistry

Volumn 115, Issue 5, 2014, Pages 819-825

  Kumar, Sushil ^a   Fajardo, J Eduardo ^b   Birge, Raymond B ^a   Sriram, Ganapathy ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CANCER GENETICS; Crk; SH2 and SH3 DOMAIN; TYROSINE PHOSPHORYLATION

Indexed keywords

CRK LIKE PROTEIN;

AGGRESSION; APOPTOSIS; BACTERIAL SURVIVAL; BREAST CANCER; CANCER CELL; CANCER GENETICS; CARBOXY TERMINAL SEQUENCE; CELL INVASION; CELL MOTILITY; CELL SURVIVAL; GLIOMA; HUMAN; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION;

CANCER GENETICS; CRK; SH2 AND SH3 DOMAIN; TYROSINE PHOSPHORYLATION;

CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-CRK; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS;

EID: 84895549289     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24749     Document Type: Review

References (44)

1. Akagi T, Shishido T, Murata K, Hanafusa H,. 2000. v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. Proc Natl Acad Sci USA 97: 7290-7295.
2. Akakura S, Kar B, Singh S, Cho L, Tibrewal N, Sanokawa-Akakura R, Reichman C, Ravichandran KS, Birge RB,. 2005. C-terminal SH3 domain of CrkII regulates the assembly and function of the DOCK180/ELMO Rac-GEF. J Cell Physiol 204: 344-351.
3. Birge RB, Hanafusa H,. 1993. Closing in on SH2 specificity. Science 262: 1522-1524.
4. Birge RB, Kalodimos C, Inagaki F, Tanaka S,. 2009. Crk and CrkL adaptor proteins: Networks for physiological and pathological signaling. Cell Commun Signal 7: 13.
5. Birge RB, Knudsen BS, Besser D, Hanafusa H,. 1996. SH2 and SH3-containing adaptor proteins: Redundant or independent mediators of intracellular signal transduction. Genes Cells 1: 595-613.
6. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N,. 2012. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404.
7. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, Marsh CB, Nana-Sinkam SP,. 2008. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373: 607-612.
8. Donaldson LW, Gish G, Pawson T, Kay LE, Forman-Kay JD,. 2002. Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide. Proc Natl Acad Sci USA 99: 14053-14058.
9. Fathers KE, Bell ES, Rajadurai CV, Cory S, Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, Grosset AA, Gaboury L, Hallet M, Siegel P, Park M,. 2012. Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res 14: R74.
10. Fathers KE, Rodrigues S, Zuo D, Murthy IV, Hallett M, Cardiff R, Park M,. 2010. CrkII transgene induces atypical mammary gland development and tumorigenesis. Am J Pathol 176: 446-460.
11. Feller SM,. 2001. Crk family adaptors-signalling complex formation and biological roles. Oncogene 20: 6348-6371.
12. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B, Zhu Z,. 2010. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 298: 50-63.
13. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N,. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1.
14. Gil-Henn H, Patsialou A, Wang Y, Warren MS, Condeelis JS, Koleske AJ,. 2013. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene 32: 2622-2630.
15. Gonfloni S, Williams JC, Hattula K, Weijland A, Wierenga RK, Superti-Furga G,. 1997. The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. EMBO J 16: 7261-7271.
16. Guris DL, Fantes J, Tara D, Druker BJ, Imamoto A,. 2001. Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat Genet 27: 293-298.
17. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G,. 2003. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112: 845-857.
18. Iwahara T, Akagi T, Fujitsuka Y, Hanafusa H,. 2004. CrkII regulates focal adhesion kinase activation by making a complex with Crk-associated substrate, p130Cas. Proc Natl Acad Sci USA 101: 17693-17698.
19. Jankowski W, Saleh T, Pai MT, Sriram G, Birge RB, Kalodimos CG,. 2012. Domain organization differences explain Bcr-Abl's preference for CrkL over CrkII. Nat Chem Biol 8: 590-596.
20. Knudsen BS, Zheng J, Feller SM, Mayer JP, Burrell SK, Cowburn D, Hanafusa H,. 1995. Affinity and specificity requirements for the first Src homology 3 domain of the Crk proteins. EMBO J 14: 2191-2198.
21. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS,. 2009. Regulation of miRNA expression by Src and contact normalization: Effects on nonanchored cell growth and migration. Oncogene 28: 4272-4283.
22. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ,., Gil-Henn H,. 2011. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res 71: 1730-1741.
23. Matsuda M, Mayer BJ, Fukui Y, Hanafusa H,. 1990. Binding of transforming protein, P47gag-crk, to a broad range of phosphotyrosine-containing proteins. Science 248: 1537-1539.
24. Matsuda M, Mayer BJ, Hanafusa H,. 1991. Identification of domains of the v-crk oncogene product sufficient for association with phosphotyrosine- containing proteins. Mol Cell Biol 11: 1607-1613.
25. Mayer BJ, Hamaguchi M, Hanafusa H,. 1988. A novel viral oncogene with structural similarity to phospholipase C. Nature 332: 272-275.
26. Mayer BJ, Hanafusa H,. 1990a. Association of the v-crk oncogene product with phosphotyrosine-containing proteins and protein kinase activity. Proc Natl Acad Sci USA 87: 2638-2642.
27. Mayer BJ, Hanafusa H,. 1990b. Mutagenic analysis of the v-crk oncogene: Requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation. J Virol 64: 3581-3589.
28. Miller CT, Chen G, Gharib TG, Wang H, Thomas DG, Misek DE, Giordano TJ, Yee J, Orringer MB, Hanash SM, Beer DG,. 2003. Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 22: 7950-7957.
29. Muralidharan V, Dutta K, Cho J, Vila-Perello M, Raleigh DP, Cowburn D, Muir TW,. 2006. Solution structure and folding characteristics of the C-terminal SH3 domain of c-Crk-II. Biochemistry 45: 8874-8884.
30. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J,. 2003. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112: 859-871.
31. Park TJ, Boyd K, Curran T,. 2006. Cardiovascular and craniofacial defects in Crk-null mice. Mol Cell Biol 26: 6272-6282.
32. Pawson T,. 2004. Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116: 191-203.
33. Pawson T, Nash P,. 2003. Assembly of cell regulatory systems through protein interaction domains. Science 300: 445-452.
34. Reichman C, Singh K, Liu Y, Singh S, Li H, Fajardo JE, Fiser A, Birge RB,. 2005. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain. Oncogene 24: 8187-8199.
35. Reichman CT, Mayer BJ, Keshav S, Hanafusa H,. 1992. The product of the cellular crk gene consists primarily of SH2 and SH3 regions. Cell Growth Differ 3: 451-460.
36. Sarkar P, Reichman C, Saleh T, Birge RB, Kalodimos CG,. 2007. Proline cis-trans isomerization controls autoinhibition of a signaling protein. Mol Cell 25: 413-426.
37. Sarkar P, Saleh T, Tzeng SR, Birge RB, Kalodimos CG,. 2011. Structural basis for regulation of the Crk signaling protein by a proline switch. Nat Chem Biol 7: 51-57.
38. Shishido T, Akagi T, Chalmers A, Maeda M, Terada T, Georgescu MM, Hanafusa H,. 2001. Crk family adaptor proteins trans-activate c-Abl kinase. Genes Cells 6: 431-440.
39. Sicheri F, Moarefi I, Kuriyan J,. 1997. Crystal structure of the Src family tyrosine kinase Hck. Nature 385: 602-609.
40. Smith-Pearson PS, Greuber EK, Yogalingam G, Pendergast AM,. 2010. Abl kinases are required for invadopodia formation and chemokine-induced invasion. J Biol Chem 285: 40201-40211.
41. Sriram G, Reichman C, Tunceroglu A, Kaushal N, Saleh T, Machida K, Mayer B, Ge Q, Li J, Hornbeck P, Kalodimos CG, Birge RB,. 2011. Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation. Oncogene 30: 4645-4655.
42. Takino T, Nakada M, Miyamori H, Yamashita J, Yamada KM, Sato H,. 2003. CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res 63: 2335-2337.
43. Tunceroglu A, Matsuda M, Birge RB,. 2010. Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia. Mol Cancer Ther 9: 3065-3073.
44. Wu X, Knudsen B, Feller SM, Zheng J, Sali A, Cowburn D, Hanafusa H, Kuriyan J,. 1995. Structural basis for the specific interaction of lysine-containing proline-rich peptides with the N-terminal SH3 domain of c-Crk. Structure 3: 215-226.